Next Article in Journal
Polish Yellow Sweet Clover (Melilotus officinalis L.) Honey, Chromatographic Fingerprints, and Chemical Markers
Next Article in Special Issue
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
Previous Article in Journal
Volatile Compound Profiling by HS-SPME/GC-MS-FID of a Core Olive Cultivar Collection as a Tool for Aroma Improvement of Virgin Olive Oil
Previous Article in Special Issue
A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma
Article

Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD

1
Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2
State Key Laboratory for Quality Research of Chinese Medicines, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China
*
Author to whom correspondence should be addressed.
Academic Editor: Tung-Hu Tsai
Molecules 2017, 22(1), 142; https://doi.org/10.3390/molecules22010142
Received: 8 December 2016 / Revised: 30 December 2016 / Accepted: 8 January 2017 / Published: 15 January 2017
(This article belongs to the Special Issue Silymarin)
Silymarin is the most commonly used herbal medicine by patients with chronic liver disease. Silymarin flavonolignans undergo rapid first-pass metabolism primarily by glucuronidation. The aims of this investigation were: (1) to determine the association of UGT1A1*28 polymorphism with the area under the plasma concentration-time curves (AUCs) for silybin A (SA) and silybin B (SB); (2) to evaluate the effect of UGT1A1*28 polymorphism on the profile of flavonolignan glucuronide conjugates found in the plasma; and (3) to investigate the role of UGT1A1 enzyme kinetics on the pharmacokinetics of SA and SB. AUCs and metabolic ratios for thirty-three patients with chronic liver disease administered oral doses of silymarin were compared between different UGT1A1*28 genotypes. The AUCs, metabolic ratios, and the profiles of major SA and SB glucuronides did not differ significantly among the three UGT1A1 genotypes. In contrast, an increase in the proportion of sulfated flavonolignan conjugates in plasma was observed in subjects with UGT1A1*28/*28 genotype compared to subjects carrying wild type alleles. Differences in SA and SB in vitro intrinsic clearance estimates for UGTIA1 correlated inversely with SA and SB exposures observed in vivo indicating a major role for UGT1A1 in silymarin metabolism. In addition, a significant difference in the metabolic ratio observed between patients with NAFLD and HCV suggests that any effect of UGT1A1 polymorphism may be obscured by a greater effect of liver disease on the pharmacokinetics of silymarin. Taken together, these results suggest the presence of the UGT1A1*28 allele does not contribute significantly to a large inter-subject variability in the pharmacokinetics of silybin A and silybin B which may obscure the ability to detect beneficial effects of silymarin in patients with liver disease. View Full-Text
Keywords: UGT1A1; polymorphism; pharmacokinetics; silymarin; silybin A; liver disease; NAFLD; HCV UGT1A1; polymorphism; pharmacokinetics; silymarin; silybin A; liver disease; NAFLD; HCV
Show Figures

Figure 1

MDPI and ACS Style

Xie, Y.; Miranda, S.R.; Hoskins, J.M.; Hawke, R.L. Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD. Molecules 2017, 22, 142. https://doi.org/10.3390/molecules22010142

AMA Style

Xie Y, Miranda SR, Hoskins JM, Hawke RL. Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD. Molecules. 2017; 22(1):142. https://doi.org/10.3390/molecules22010142

Chicago/Turabian Style

Xie, Ying, Sonia R. Miranda, Janelle M. Hoskins, and Roy L. Hawke 2017. "Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD" Molecules 22, no. 1: 142. https://doi.org/10.3390/molecules22010142

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop